Organogenesis Holdings (ORGO) reported $564M in revenue for fiscal 2025, +17.0% year on year. That ranks #2139 by revenue among 2853 SEC filers and #207 in Healthcare. Net income was $37.0M, a net margin of 6.6%. Revenue has grown 16.9% a year on average since 2016 ($139M then). The fiscal 2025 balance sheet shows $599M in total assets, $93.7M in cash and $66.6M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $564M | +17.0% | FY20252025-12-31 |
| Gross profitGrossProfit | $366M | +12.1% | FY20242024-12-31 |
| Operating incomeOperatingIncomeLoss | $44.7M | +$46.0M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $37.0M | +4,011.1% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$10.3M | −$24.5M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $14.2M | +41.1% | FY20252025-12-31 |
| Total assetsAssets | $599M | +20.3% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $300M | +14.2% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $93.7M | −30.9% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $66.6M | −6.6% | FY20232023-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $37.2M | −$53.2M | Open → |
| Q2 20262026-06-30 | $43.8M | −$96.3M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Organogenesis Holdings Inc.
- Ticker
- ORGO
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001661181
Filings
- 10-QAug 6, 2026Open filing →
- 10-QMay 7, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Catalyst PharmaceuticalsCPRX | $589M | $214M |
| AlvotechALVO | $586M | $27.9M |
| BioventusBVS | $568M | $22.7M |
| Organogenesis HoldingsORGO | $564M | $37.0M |
| HUTCHMED (China)HCM | $549M | $457M |
| AtricureATRC | $535M | −$11.4M |
| Mirum PharmaceuticalsMIRM | $521M | −$23.4M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Organogenesis Holdings — Key figures |url=https://companiesranked.com/en/company/organogenesis-holdings |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Organogenesis Holdings — Key figures. CompaniesRanked. https://companiesranked.com/en/company/organogenesis-holdingsBibTeX
@misc{companiesranked-en-company-organogenesis-holdings-2026,
author = {{CompaniesRanked}},
title = {{Organogenesis Holdings — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/organogenesis-holdings}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-076730 · February 26, 2026
{{cite web |title=Organogenesis Holdings — Key figures — 10-K (0001193125-26-076730) |url=https://www.sec.gov/Archives/edgar/data/1661181/000119312526076730/orgo-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.